Motor neuron dysfunction in a mouse model of ALS: gender-dependent effect of P2X7 antagonism - PubMed (original) (raw)
. 2013 Sep 6;311(1-2):69-77.
doi: 10.1016/j.tox.2013.04.004. Epub 2013 Apr 11.
Affiliations
- PMID: 23583883
- DOI: 10.1016/j.tox.2013.04.004
Motor neuron dysfunction in a mouse model of ALS: gender-dependent effect of P2X7 antagonism
Chiara Cervetto et al. Toxicology. 2013.
Abstract
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative progressive currently untreatable disease, characterized by selective motor neuron degeneration; the incidence and prevalence of ALS are greater in men than in women. Although some important mechanisms that might contribute to the death of motor neurons have been identified, the mechanisms underlying disease pathophysiology are still uncertain. In particular, the mechanisms underlying the role of gender in ALS and whether treatments should take into account sexual dimorphism remain only partially understood. Recently, the P2X7 receptor for ATP was reported to display neurotoxic potential in motor neuron disorders, and antagonism of the receptor has been suggested to be helpful in these disorders. Studying transgenic mice with superoxide dismutase 1 gene mutations, widely used as model for ALS, may provide a better understanding of pathogenic mechanisms and of toxicity towards motor neurons, also possibly helping to understand whether treatments for ALS should take into account sexual dimorphism. The aim of the work was (1) investigating on gender-dependence of disease progression in the standard model for ALS - the transgenic mouse bearing superoxide dismutase 1 gene mutations - and (2) assessing if a P2X7 receptor antagonist treatment should take into account sexual dimorphism. We evaluated if gender affect the disease course, the motor performance, the weight loss and the lifespan in mice overexpressing mutant superoxide dismutase 1. We measured motor impairment, motor strength and coordination by rotarod and grip strength testing. Further, we assessed if a treatment with the P2X7 receptor antagonist Brilliant Blue G - a dye that can cross the blood-brain barrier, has low toxicity, and has exhibited therapeutic effects in animal models of neurodegenerative diseases - impact on the disease progression, in male and female ALS mice. We found that (1) the onset and the disease progression, and the survival were dependent on gender: male performed worst than female, lost body weight and died before; (2) treatment with the P2X7 receptor antagonist Brilliant Blue G ameliorated the disease progression. The treatment effect was gender-dependent: amelioration was greater in male than in female. In conclusions, we suggest that not only pathogenetic mechanism of motor neuron toxicity but also the drug treatment effectiveness may depend on gender; sexual dimorphism should be considered when investigating on ALS treatment efficacy in the ALS animal model. Our findings also point on the potential relevance of P2X7 receptor antagonism for ALS treatment, and highlight the importance of adopting a sex-specific approach to searching for treatment of ALS.
Keywords: ALS; Amyotrophic lateral sclerosis; BBG; Brilliant Blue G; Cu/Zn superoxide dismutase 1; Gender difference; Motor neuron; P2X7 receptor; SOD1; SOD1/G93A mice; amyotrophic lateral sclerosis; d; days of age; transgenic mice carrying a high copy number of a transgene encoding a variant of human superoxide dismutase 1 with a G93A mutation (Gly93Ala substitution).
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.
Similar articles
- Chronic administration of P2X7 receptor antagonist JNJ-47965567 delays disease onset and progression, and improves motor performance in ALS SOD1G93A female mice.
Ruiz-Ruiz C, García-Magro N, Negredo P, Avendaño C, Bhattacharya A, Ceusters M, García AG. Ruiz-Ruiz C, et al. Dis Model Mech. 2020 Oct 30;13(10):dmm045732. doi: 10.1242/dmm.045732. Dis Model Mech. 2020. PMID: 33174532 Free PMC article. - The NADPH oxidase pathway is dysregulated by the P2X7 receptor in the SOD1-G93A microglia model of amyotrophic lateral sclerosis.
Apolloni S, Parisi C, Pesaresi MG, Rossi S, Carrì MT, Cozzolino M, Volonté C, D'Ambrosi N. Apolloni S, et al. J Immunol. 2013 May 15;190(10):5187-95. doi: 10.4049/jimmunol.1203262. Epub 2013 Apr 15. J Immunol. 2013. PMID: 23589615 - Spinal cord pathology is ameliorated by P2X7 antagonism in a SOD1-mutant mouse model of amyotrophic lateral sclerosis.
Apolloni S, Amadio S, Parisi C, Matteucci A, Potenza RL, Armida M, Popoli P, D'Ambrosi N, Volonté C. Apolloni S, et al. Dis Model Mech. 2014 Sep;7(9):1101-9. doi: 10.1242/dmm.017038. Epub 2014 Jul 18. Dis Model Mech. 2014. PMID: 25038061 Free PMC article. - [Development of motor neuron restorative therapy in amyotrophic lateral sclerosis using hepatocyte growth factor].
Aoki M, Warita H, Suzuki N, Itoyama Y. Aoki M, et al. Rinsho Shinkeigaku. 2009 Nov;49(11):814-7. doi: 10.5692/clinicalneurol.49.814. Rinsho Shinkeigaku. 2009. PMID: 20030218 Review. Japanese. - Mitochondrial dysfunction and its role in motor neuron degeneration in ALS.
Manfredi G, Xu Z. Manfredi G, et al. Mitochondrion. 2005 Apr;5(2):77-87. doi: 10.1016/j.mito.2005.01.002. Mitochondrion. 2005. PMID: 16050975 Review.
Cited by
- Dietary Vitamin D3 Restriction Exacerbates Disease Pathophysiology in the Spinal Cord of the G93A Mouse Model of Amyotrophic Lateral Sclerosis.
Moghimi E, Solomon JA, Gianforcaro A, Hamadeh MJ. Moghimi E, et al. PLoS One. 2015 May 28;10(5):e0126355. doi: 10.1371/journal.pone.0126355. eCollection 2015. PLoS One. 2015. PMID: 26020962 Free PMC article. - Duality of P2X7 Receptor in Amyotrophic Lateral Sclerosis.
Volonté C, Amadio S, Liguori F, Fabbrizio P. Volonté C, et al. Front Pharmacol. 2020 Jul 24;11:1148. doi: 10.3389/fphar.2020.01148. eCollection 2020. Front Pharmacol. 2020. PMID: 32792962 Free PMC article. No abstract available. - Novel P2X7 Antagonist Ameliorates the Early Phase of ALS Disease and Decreases Inflammation and Autophagy in SOD1-G93A Mouse Model.
Apolloni S, Fabbrizio P, Amadio S, Napoli G, Freschi M, Sironi F, Pevarello P, Tarroni P, Liberati C, Bendotti C, Volonté C. Apolloni S, et al. Int J Mol Sci. 2021 Sep 30;22(19):10649. doi: 10.3390/ijms221910649. Int J Mol Sci. 2021. PMID: 34638992 Free PMC article. - Animal Models for the Investigation of P2X7 Receptors.
Sluyter R, Adriouch S, Fuller SJ, Nicke A, Sophocleous RA, Watson D. Sluyter R, et al. Int J Mol Sci. 2023 May 4;24(9):8225. doi: 10.3390/ijms24098225. Int J Mol Sci. 2023. PMID: 37175933 Free PMC article. Review. - P2X7 receptor antagonism in amyotrophic lateral sclerosis.
Sluyter R, Bartlett R, Ly D, Yerbury JJ. Sluyter R, et al. Neural Regen Res. 2017 May;12(5):749-750. doi: 10.4103/1673-5374.206643. Neural Regen Res. 2017. PMID: 28616029 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous